Reneo Pharmaceuticals/RPHM

$1.64

-0.61%
-
1D1W1MYTD1YMAX

About Reneo Pharmaceuticals

Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The Company's product candidate, mavodelpar, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARd). Mavodelpar helps in increasing the transcription of genes involved in mitochondrial function and increases fatty acid oxidation (FAO) and may increase the production of new mitochondria. The Company is developing REN001 in the two rare genetic diseases that present with myopathy and have unmet medical needs: primary mitochondrial myopathies (PMM), and long-chain fatty acid oxidation disorders (LC-FAOD).
Ticker
RPHM
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Michael Grey
Employees
55
Headquarters
Irvine, United States

RPHM Metrics

BasicAdvanced
$54.96M
Market cap
-
P/E ratio
-$2.37
EPS
-
Beta
-
Dividend rate

What the Analysts think about RPHM

Analyst Ratings

Majority rating from 6 analysts.
Hold

Price Targets

Average projection from 5 analysts.
6.71% upside
High $3.00
Low $1.00
$1.64
Current price
$1.75
Average price target

RPHM Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-19.1M
-2.05%
Profit margin
0%
-

RPHM Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 0.25%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.56
-$0.60
-$0.65
-$0.57
-
Expected
-$0.60
-$0.60
-$0.52
-$0.57
-$0.62
Surprise
-6.79%
-0.66%
25.81%
-0.25%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Reneo Pharmaceuticals stock

Buy or sell Reneo Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing